Encephalopathy, delirium, and agitation are documented symptoms of coronavirus disease (COVID-19) infection, but research into the management of agitation in the setting of COVID-19 and pre-existing neuropsychiatric disease is ongoing. We present a 55-year-old male patient with early-onset Alzheimer disease and deteriorating mental and functional status who presented to our institution with agitation and persistent COVID-19 positivity on polymerase chain reaction testing. His agitation was improved through pharmacologic optimization including the avoidance of benzodiazepines and initiation of clonidine and prazosin, which temporally coincided with the resolution of his nearly 2-month long COVID-19 positivity.
Home Alzheimer's Research An Agitated Patient With COVID-19 Infection and Early-onset Alzheimer Disease
Latest article
Take it from the rats: A junk food diet can cause long-term damage to...
A new USC-led study on rats that feasted on a high-fat, sugary diet raises the possibility that a junk food-filled diet in teens may...
Repurposing non-pharmacological interventions for Alzheimer’s disease through link prediction on biomedical literature
The complete workflow is depicted in Fig. 1. To investigate the association between NPIs and AD, we initially conducted preprocessing and integration of biomedical triples...
Degenerative Dementias and Their Medical Care in the Movies
Compared with other neurologic problems, few films have been dedicated to degenerative dementia. To our knowledge, this is the first systematic review about the...
